Known safety concerns, contraindications, and risk factors.
Active or prior cancer
GH secretagogues, IGF-1 analogs, and BPC-157 may promote tumor growth or recurrence through mitogenic and angiogenic pathways.
Elderly with cardiac history
MK-677 caused heart failure in elderly trial participants. GH-mediated fluid retention and cardiac remodeling increase risk in those with pre-existing cardiac conditions.
Pregnancy or breastfeeding
No safety data exists for any of these compounds during pregnancy or lactation. Hormonal and growth factor modulation poses unknown risks to fetal and infant development.
Competitive athletes (WADA-tested)
GH secretagogues, IGF-1 analogs, myostatin inhibitors, and GLP-1 RAs are prohibited by WADA. Use results in anti-doping violations and competition bans.
Diabetes or pre-diabetic state
MK-677 and CJC-1295 reduce insulin sensitivity and elevate blood glucose. IGF-1 LR3 causes unpredictable hypoglycemia. Combined glucose disruption is dangerous for diabetics.